Company research
Adamas Pharmaceuticals Inc
CIK 1328143Updated Nov 16, 2026
Securities
Historical securities (1)
ADMS · NASDAQ · equity · closed Nov 24, 2021Name history
NeuroMolecular Pharmaceuticals Inc · through Jul 17, 2006
ADMS price & chart
Historical security
This listing closed Nov 24, 2021. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2020 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 120,029,000Source | 162,158,000Source | 234,814,000Source | 186,176,000Source |
| Property, Plant and Equipment, NetUSD | 1,598,000Source | 2,449,000Source | 3,652,000Source | 3,132,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 71,660,000Source | 65,774,000Source | 56,605,000Source | 91,316,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 8,042,000Source | 5,770,000Source | 5,511,000Source | 367,000Source |
| Inventory, NetUSD | 7,294,000Source | 5,267,000Source | 5,121,000Source | 1,704,000Source |
| Assets, CurrentUSD | 111,736,000Source | 150,320,000Source | 228,373,000Source | 179,175,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 13,035,000Source | 6,676,000Source | 6,871,000Source | 3,662,000Source |
| Operating Lease, Right-of-Use AssetUSD | 6,657,000Source | 8,048,000Source | — | — |
| Other Assets, NoncurrentUSD | — | — | — | 878,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 170,005,000Source | 163,051,000Source | 144,929,000Source | 120,050,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 34,000Source | 33,000Source | 32,000Source | 28,000Source |
| Retained Earnings (Accumulated Deficit)USD | -505,287,000Source | -447,884,000Source | -342,698,000Source | -211,699,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 0Source | 16,000Source | -264,000Source | -167,000Source |
| Stockholders' Equity Attributable to ParentUSD | -49,976,000Source | -893,000Source | 89,885,000Source | 66,126,000Source |
| Additional Paid in Capital, Common StockUSD | 455,277,000Source | 446,942,000Source | 432,815,000Source | 277,964,000Source |
| Liabilities and EquityUSD | 120,029,000Source | 162,158,000Source | 234,814,000Source | 186,176,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 34,867,000Source | 26,948,000Source | 24,276,000Source | 16,607,000Source |
| Operating Lease, Liability, CurrentUSD | 1,855,000Source | 1,669,000Source | — | — |
| Accounts Payable, CurrentUSD | 2,144,000Source | 6,932,000Source | 6,570,000Source | 3,878,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,453,000Source | 8,272,000Source | — | — |
| Other Liabilities, NoncurrentUSD | 2,378,000Source | 2,157,000Source | 3,196,000Source | 796,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 27,164,000Source | 16,117,000Source | 17,194,000Source | 12,385,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 83,400,000Source | 132,600,000Source | — | 176,400,000Source |
| Deferred Tax Liabilities, NetUSD | 1,907,000Source | 2,339,000Source | — | — |
| Long-term Debt, Current MaturitiesUSD | 3,657,000Source | 2,041,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 126,307,000Source | 125,674,000Source | 117,457,000Source | 102,647,000Source |
| Short-term InvestmentsUSD | 11,705,000Source | 66,833,000Source | 154,265,000Source | 82,126,000Source |
cash flow · annual statements
| Line item | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 851,000Source | 1,214,000Source | 1,460,000Source | 1,194,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,431,000Source | 12,852,000Source | 15,786,000Source | 13,367,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 2,272,000Source | 259,000Source | 5,144,000Source | -427,000Source |
| Increase (Decrease) in InventoriesUSD | 2,205,000Source | 970,000Source | 3,273,000Source | 1,646,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | 2,759,000Source | 333,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -50,708,000Source | -80,779,000Source | -104,223,000Source | -66,827,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 54,940,000Source | 88,863,000Source | -69,338,000Source | 25,565,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 0Source | 18,000Source | 1,064,000Source | 1,258,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,654,000Source | 1,085,000Source | 138,850,000Source | 108,843,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 5,886,000Source | 9,169,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 71,660,000Source | 65,774,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 11,738,000Source | 6,450,000Source | 2,618,000Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,431,000Source | 12,852,000Source | 15,786,000Source | 13,367,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 83,400,000Source | 132,600,000Source | — | 176,400,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 0Source | -123,000Source | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | -1,730,000Source |
| Inventory Write-downUSD | 595,000Source | 884,000Source | 232,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -57,403,000Source | -105,186,000Source | -130,999,000Source | -89,490,000Source |
| Operating ExpensesUSD | — | — | — | 88,497,000Source |
| Proceeds from Issuance of Common StockUSD | 1,041,000Source | 0Source | 134,268,000Source | 0Source |
| Proceeds from Issuance of Long-term DebtUSD | — | 0Source | 0Source | 99,600,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 106,810,000Source | 182,750,000Source | 132,080,000Source | 89,333,000Source |
| Proceeds from Stock Options ExercisedUSD | 176,000Source | 310,000Source | 3,345,000Source | — |
income statement · annual statements
| Line item | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|
| Total RevenueUSD | 74,461,000Source | 54,637,000Source | 34,046,000Source | 571,000Source |
| Cost of RevenueUSD | 2,038,000Source | 2,469,000Source | 633,000Source | 17,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 106,841,000Source | 114,369,000Source | 109,135,000Source | 61,312,000Source |
| Operating Income (Loss)USD | -44,164,000Source | -92,235,000Source | -115,022,000Source | -87,926,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | -1,730,000Source |
| Net Income (Loss) Attributable to ParentUSD | -57,403,000Source | -105,186,000Source | -130,999,000Source | -89,490,000Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 118,625,000Source | 146,872,000Source | 149,068,000Source | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | -1,730,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -57,378,000Source | -105,186,000Source | -130,999,000Source | -91,220,000Source |
| Interest ExpenseUSD | 13,987,000Source | 15,044,000Source | 19,092,000Source | 4,645,000Source |
| Operating ExpensesUSD | — | — | — | 88,497,000Source |
| Research and Development ExpenseUSD | 9,746,000Source | 30,034,000Source | 39,300,000Source | 27,168,000Source |
| Sales Revenue, Goods, Net (Deprecated 2018-01-31)USD | — | — | — | 568,000Source |